KALA BIO (NASDAQ:KALA) is a clinical-stage biopharmaceutical company focused on developing novel therapies for ophthalmic diseases. Headquartered in Cambridge, Massachusetts, the company leverages a proprietary nanoparticle-based drug delivery platform to create topical eye treatments that aim to improve drug penetration, extend dosing intervals and enhance patient convenience. Since its founding in 2017, Kala Bio has positioned itself as a leader in next-generation ocular therapeutics, targeting conditions such as dry eye disease, allergic conjunctivitis and postoperative ocular pain.
The company’s flagship product, EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is approved by the U.S. Food and Drug Administration for the short-term treatment of the signs and symptoms of dry eye disease. EYSUVIS utilizes Kala Bio’s DuraSite® technology to achieve sustained drug delivery to ocular tissues, representing one of the first commercial validations of the platform. In parallel, Kala Bio’s pipeline includes multiple candidates in various stages of clinical development for indications ranging from chronic dry eye to acute ocular inflammation, reflecting its commitment to addressing unmet needs in eye care.
Historically, Kala Bio began as a spin-out from academic research in nanotechnology and ophthalmology. Early collaborations with leading research institutions helped establish the foundational science for its proprietary delivery system. Over the years, the company has expanded its geographic reach, forging distribution and licensing agreements in Europe and Asia while maintaining a focus on the U.S. market. Kala Bio continues to explore strategic partnerships to broaden patient access to its innovative therapies around the globe.
Leadership at Kala Bio comprises industry veterans with extensive experience in biopharmaceutical development, ophthalmology and global commercialization. The executive team draws on expertise gained at major pharmaceutical and medical device companies, ensuring a blend of scientific rigor and commercial insight. Guided by a board of directors that includes renowned clinicians and life sciences investors, Kala Bio remains dedicated to advancing its pipeline and delivering transformative eye care solutions to patients worldwide.
